


Anti-NR3C2 Recombinant Antibody Products

Anti-NR3C2 Products
-
- Derivation: Mouse
- Species Reactivity: Human
- Type: Mouse IgG1
- Application: WB, FC, ICC, IF, IHC, Neut
-
- Species Reactivity: Human
- Application: ELISA, IP, IHC-P, WB, FC, ICC/IF
- Recombinant Mouse Anti-NR3C2 Antibody (H10E4C9F) (NEUT-1789CQ)
-
- Species Reactivity: Human, Mouse, Rat, Chicken, Rabbit, Sheep
- Type: IgG1
- Application: WB, Neut, Flow, ICC/IF, IHC, IHC-P
- AbPlus™ Anti-NR3C2 Magnetic Beads (VS-0724-YC351) (VS-0724-YC351)
-
- Target: NR3C2
- Target Species: Human, Mouse, Rat
- Application: IP, Protein Purification
- Anti-NR3C2 Immunohistochemistry Kit (VS-0325-XY1515)
-
- Species Reactivity: Human, Mouse, Rat
- Target: NR3C2
- Application: IHC
- Anti-Mouse NR3C2 Immunohistochemistry Kit (VS-0525-XY4962)
-
- Species Reactivity: Human, Mouse, Rat, Chicken, Rabbit, Sheep
- Target: NR3C2
- Application: IHC
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
At Creative Biolabs, we specialize in developing state-of-the-art recombinant antibodies targeting NR3C2, which play a pivotal role in advancing biomedical research. Leveraging our sophisticated technological infrastructure, we ensure that each antibody product meets the most stringent quality and performance benchmarks. Our extensive collection of recombinant antibodies underscores our dedication to facilitating scientific exploration, offering researchers consistent reliability and cost-effective solutions. Beyond our high - quality offerings, we provide comprehensive technical assistance tailored to support researchers at every stage of their projects. Collaborating with Creative Biolabs grants you access to innovative research tools and a team of experts who are deeply invested in helping you achieve your scientific objectives.
NR3C2: A Promising Target in Cardiovascular Renal and Metabolic Disorders
The mineralocorticoid receptor (MR), or NR3C2, is a nuclear receptor that plays a central role in maintaining the body's electrolyte balance, regulating blood pressure, and ensuring proper fluid homeostasis. Hormones such as aldosterone and cortisol act as its main activators. When NR3C2 malfunctions, it can lead to various health issues. Specifically, an imbalance in NR3C2 activity has been linked to hypertension, heart failure, and kidney diseases, highlighting its significance in human health and disease. In cardiovascular disorders, overactivation of NR3C2 can contribute to inflammation, fibrosis, and vascular dysfunction. In the kidneys, its abnormal signaling may lead to sodium retention and fluid imbalance, worsening chronic kidney disease. Emerging studies also suggest a role for NR3C2 in metabolic syndrome and certain neurological disorders, due to its expression in the brain. As such, NR3C2 represents a valuable target for therapeutic intervention in a range of diseases, especially those involving cardiovascular and renal systems.
Alternative Names
Complement NR3C2; MR; MCR; MLR; NR3C2VIT
Background
This gene encodes the mineralocorticoid receptor, which mediates aldosterone actions on salt and water balance within restricted target cells. The protein functions as a ligand-dependent transcription factor that binds to mineralocorticoid response elements in order to transactivate target genes. Mutations in this gene cause autosomal dominant pseudohypoaldosteronism type I, a disorder characterized by urinary salt wasting. Defects in this gene are also associated with early onset hypertension with severe exacerbation in pregnancy. Alternative splicing results in multiple transcript variants.
Disease related genes, FDA approved drug targets, Human disease related genes, Nuclear receptors, Transcription factors
Intracellular
Cell type enhanced (Excitatory neurons, Inhibitory neurons, Astrocytes, Oligodendrocyte precursor cells, Microglial cells)
Immune cell enhanced (MAIT T-cell)
Cell line enhanced (hTERT-RPE1, HUVEC TERT2, Karpas-707, PC-3, RPTEC TERT1, TIME)
Heteromultimeric cytoplasmic complex with HSP90, HSP70, and FKBP4, in the absence of ligand. After ligand binding, it translocates to the nucleus and binds to DNA as a homodimer and as a heterodimer with NR3C1. May interact with HSD11B2 in the absence of ligand. Binds the coactivators NCOA1, NCOA2, TIF1 and NRIP1.
DNA-binding, Receptor
Anti-NR3C2 rAb Products
We strive to accelerate scientific progress by providing high-quality anti-NR3C2 recombinant antibodies, outstanding value, and reliable technical assistance to support your research needs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
MOB-2155z | Mouse Anti-NR3C2 Recombinant Antibody (clone 35A10) | Human | Mouse | WB; FC; ICC; IF; IHC; Neut |
MOB-2382CT | Recombinant Mouse anti-Human NR3C2 Monoclonal antibody (FQS6265) | Human | Mouse | ELISA; IP; IHC-P; WB; FC; ICC; IF |
NEUT-1789CQ | Recombinant Mouse Anti-NR3C2 Antibody (H10E4C9F) | Human; Mouse; Rat; Chicken; Rabbit; Sheep | Mouse | WB; Neut; FC; ICC; IF; IHC; IHC-P |
Customer Reviews

Mouse Anti-NR3C2 Recombinant Antibody (clone 35A10) (CAT#: MOB-2155z)

Recombinant Mouse anti-Human NR3C2 Monoclonal antibody (FQS6265) (CAT#: MOB-2382CT)
rAb Production
Backed by extensive years of hands - on experience in the intricate fields of recombinant antibody development and optimization, we have honed our expertise to perfection. Our team of skilled scientists employs cutting - edge techniques and innovative methodologies to create antibodies that are not only of superior quality but also highly effective. We understand the urgency of research needs, and our streamlined processes allow us to efficiently deliver products that adhere to the most stringent industry standards, ensuring rapid turnaround without compromising on excellence.
Featured Anti-NR3C2 Recombinant Antibody Production Platforms
Fig.1 Milligram-scale recombinant antibody production.
Fig.2 Gram-scale recombinant antibody production.
rAb Modalities
At Creative Biolabs, we're dedicated to offering researchers an extensive range of state-of-the-art, top-notch recombinant antibodies in diverse formats. Our profound expertise covers various antibody engineering approaches, and we complement our products with outstanding custom engineering services tailored to fulfill your specific research needs.
Fig.3 Full Length Anti-NR3C2 Recombinant Antibody Production and Modalities.
Drug Information Targeting NR3C2
Table 1. Therapeutic approaches targeting NR3C2 in clinical development.
Research phase | Company | Classification | Indications | Details |
Launched - 2021 | Adcock Ingram | Combinations | Endometriosis | It is a fixed-dose oral contraceptive combining estetrol and drospirenone, developed by Mithra Pharmaceuticals and licensed to partners including Fuji Pharma, Gedeon Richter, and Mayne Pharma for commercialization across multiple regions. |
Launched - 2021 | Bayer | Small Molecules |
Chronic kidney disease; Diabetic nephropathy |
It is an oral non-steroidal mineralocorticoid receptor antagonist developed by Bayer for treating chronic kidney disease associated with type 2 diabetes, with additional clinical evaluation ongoing for various kidney and heart conditions. |
Launched - 2019 | Daiichi Sankyo | Small Molecules |
Aldosteronism; Diabetic nephropathy |
It is a mineralocorticoid receptor antagonist developed by Daiichi Sankyo, originally licensed from Exelixis, and approved in Japan for essential hypertension, with ongoing phase III trials for diabetic nephropathy. |
Launched - 2003 | Berlex | Combinations |
Menopausal symptoms; Osteoporosis, postmenopausal |
It is a continuous combined hormone replacement therapy developed by Bayer's subsidiaries for managing menopausal symptoms and preventing postmenopausal osteoporosis, first launched in 2003. |
Launched - 2000 | Schering AG | Combinations |
Endometriosis; Premenstrual syndrome |
It is an oral contraceptive combining drospirenone and ethinylestradiol, developed by Schering AG (now Bayer), also approved for treating PMDD, moderate acne, dysmenorrhea, and endometriosis across multiple regions. |
Phase III | AstraZeneca | Combinations |
Chronic kidney disease; Heart failure |
It is a fixed-dose combination of balcinrenone and dapagliflozin being developed by AstraZeneca for the treatment of chronic heart failure and kidney-related conditions including CKD with albuminuria. |
If you need further details about the NR3C2 target, please don't hesitate to contact us by phone or email. Our experienced team is always happy to provide guidance and help resolve any issues you may encounter during your experiments, ensuring you have the support necessary for successful research.